Coloplast As Sp/Adr (CLPBY) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you, and good morning, and welcome to our Q1 25-26 conference call. I'm Lars Rasmussen, interim CEO of Codoplast, and I'm joined by CFO Anders Lonning Skogård and our investor relations team. We will start with a short presentation by Anders and myself, and then open up for questions. And please turn to slide number three. We delivered 6% organic revenue growth and 3% EBIT growth in constant currencies before special items. Return on invested capital after tax and before special items landed at 15% on par with last year's adjusted figure. We had a soft start to the year as expected. However, with a significant more turbulent quarter in caresses than we would have anticipated. I'll get back to that in a moment. For the year, we maintain our guidance of around 7% organic growth. We'll lower our growth expectations for Kerasis to around 10% amidst significant market uncertainty in the outpatient setting, but raise our outlook for interventional reality to high single digits following a strong start and improved outlook for the year. Before we dive further into the quarterly performance and outlook for the year, let me begin with a brief comment on our leadership team. In December, we announced two important changes to the executive leadership team. EVP of People and Culture, Dr. Rønnau, has decided to leave Coloplast to pursue the next chapter in her career, and Tommy Johns, Executive Vice President of Interventional Neurology, has decided to retire after more than a decade in Coloplast and more than three decades in the global life science industry. An external search is currently ongoing to identify a new leader, for the Global People and Culture Function, while Kevin Hartage will step into the role of EVP interventional urology on February 9th. Kevin brings ext...